In addition to promoting CD93 expression in pMCs, the tumor also activates the CD93 pathway in pMCs because we found that C1q was responsible for CD93-mediated inhibition of CCL21 production by pMCs, and the C1q level was enhanced in both mice with lung tumors and lung tumor patients. This evidence concerns the gene CD93 and neoplasm.